MuscleMecca Crew
MuscleMecca Crew
Staff
Author
- Joined
- May 11, 2012
- Messages
- 4,318
- Points
- 83
The question surfaces in nearly every online men's health forum: if testosterone replacement therapy raises serum testosterone on its own, why do so many clinics add human chorionic gonadotropin to the protocol?
The answer sits in a set of numbers most patients never see before their first injection.
A randomized clinical trial published in the May 2005 issue of the Journal of Clinical Endocrinology & Metabolism measured what happens inside the testes when men take exogenous testosterone. Researchers led by Andrea D. Coviello randomized 29 men with normal reproductive physiology to 200 mg of testosterone enanthate weekly plus either saline placebo or 125, 250, or 500 IU of HCG every other day for three weeks.
In the placebo group, luteinizing hormone fell to 5% of baseline. Follicle-stimulating hormone fell to 3%. Intratesticular testosterone dropped 94%, from 1,234 nmol per liter to 72 nmol per liter.
HCG and luteinizing hormone bind the same receptor, designated LHCGR, expressed on the Leydig cells of the testes. LH binding stimulates testosterone production. HCG binding at the same site produces a comparable downstream response.
The two hormones are not pharmacologically identical. A study by Livio Casarini and colleagues at the University of Modena and Reggio Emilia, published in PLoS ONE in October 2012 (Volume 7, Issue 10, article e46682), compared the two at the receptor level. The authors concluded that "hCG is more potent on cAMP production, while hLH is more potent on ERK and AKT activation," and that the LHCGR "is able to differentiate the activity of hLH and hCG."
For clinical purposes the more relevant difference is duration. Endogenous LH is secreted in pulses and clears within minutes. HCG persists substantially longer, which is why administration every second or third day can substitute for continuous pituitary signaling.
Exogenous testosterone interrupts that loop. The hypothalamus and pituitary register adequate serum levels and reduce gonadotropin output, as documented in the Coviello data above.
Two consequences follow.
The first is testicular atrophy. Leydig cells deprived of LH stimulation reduce in volume, and most men on unsupported testosterone therapy report some reduction in testicular size within several months.
The second is suppression of spermatogenesis, and it is the more consequential of the two.
Sperm production depends on intratesticular testosterone rather than serum testosterone. The Coviello group measured baseline intratesticular testosterone at 1,174 nmol per liter against a baseline serum testosterone of 14.1 nmol per liter, meaning serum concentration represented 1.2% of the intratesticular concentration. Exogenous testosterone raises the smaller of those two numbers while collapsing the larger one.
The clinical result is well characterized. A 2013 paper in the Journal of Urology (Volume 189, Issue 4, pages 647 to 650) opens by stating that testosterone replacement therapy "results in decreased serum gonadotropins and intratesticular testosterone, and impairs spermatogenesis, leading to azoospermia in 40% of patients".
The 2010 Endocrine Society clinical practice guideline recommended against testosterone therapy outright "in those desiring fertility”.
HCG circumvents the suppression because it does not depend on pituitary output. It stimulates LHCGR directly, so Leydig cells continue producing testosterone locally irrespective of how suppressed endogenous signaling has become.
Hsieh and colleagues at Baylor College of Medicine retrospectively reviewed 26 hypogonadal men, mean age 35.9 years, receiving either daily topical gel or weekly intramuscular testosterone alongside 500 IU of intramuscular HCG every other day. Pretreatment semen parameters were 2.9 mL volume, 35.2 million per mL density, and 49.0% motility. Over more than a year of follow-up, the authors reported no significant differences in semen parameters and no patient becoming azoospermic. Nine of the 26 men contributed to a pregnancy during the study period.
The sample was small, the design retrospective, and individual results vary.
Return of spermatogenesis or improved counts was documented in 47 of the 49 men, or 95.9%. Mean time to return was 4.6 months, with a mean first density of 22.6 million per mL. No participant discontinued because of adverse events (Wenker et al., PMID 25904023).
Those were recovery doses roughly six to twelve times typical maintenance dosing, administered under specialist supervision.
There are defensible clinical reasons as well. A patient with a completed family, no concern about testicular volume, and no intention of discontinuing therapy may reasonably decline. Some providers prefer to establish a stable testosterone dose before adding adjuncts, revisiting the question at the three-month follow-up labs.
The distinction is whether the conversation occurred. A 29-year-old prescribed testosterone with no fertility discussion, no mention of enclomiphene, and no HCG offered on request represents a different situation than an informed decision to omit it.
Scheduling varies. Some protocols place HCG on non-testosterone injection days, others administer both on the same day. No strong comparative evidence favors either arrangement for maintenance purposes.
Reconstituted HCG requires refrigeration and has a limited shelf life after mixing, which affects vial sizing and reorder frequency.
None of the above constitutes a protocol to follow independently. Dosing decisions depend on baseline labs, follow-up labs, treatment goals, and provider judgment.
A clinic that has considered the question typically answers directly and asks about family planning in return.
Clinics that name a medical director are more likely to publish complete protocols, since a specific licensed clinician is accountable for their content.
Some providers list adjuncts openly, presenting HCG as part of a supervised TRT protocol with dosing and pricing disclosed before signup. Whether HCG is appropriate for any individual patient still requires provider evaluation and baseline lab work. Telehealth hormone services are generally limited to patients aged 21 and older in states where the clinic's providers hold active licenses, and no clinic can promise a prescription in advance of that evaluation.
For patients under 40, or any patient who may want children, the 94% reduction in intratesticular testosterone documented under unsupported testosterone therapy is a measured outcome rather than a theoretical risk. Reversal, where achieved, averaged 4.6 months in the Wenker series.
The question is worth raising at intake rather than after a semen analysis.
Educational content only, not medical advice. Individual results vary. Consult a licensed healthcare provider who has reviewed your bloodwork before starting or changing hormone therapy.
The answer sits in a set of numbers most patients never see before their first injection.
A randomized clinical trial published in the May 2005 issue of the Journal of Clinical Endocrinology & Metabolism measured what happens inside the testes when men take exogenous testosterone. Researchers led by Andrea D. Coviello randomized 29 men with normal reproductive physiology to 200 mg of testosterone enanthate weekly plus either saline placebo or 125, 250, or 500 IU of HCG every other day for three weeks.
In the placebo group, luteinizing hormone fell to 5% of baseline. Follicle-stimulating hormone fell to 3%. Intratesticular testosterone dropped 94%, from 1,234 nmol per liter to 72 nmol per liter.
What HCG Actually Is
Human chorionic gonadotropin is a glycoprotein hormone, best known as the analyte detected by home pregnancy tests. Its role in male hormone therapy comes from receptor overlap.HCG and luteinizing hormone bind the same receptor, designated LHCGR, expressed on the Leydig cells of the testes. LH binding stimulates testosterone production. HCG binding at the same site produces a comparable downstream response.
The two hormones are not pharmacologically identical. A study by Livio Casarini and colleagues at the University of Modena and Reggio Emilia, published in PLoS ONE in October 2012 (Volume 7, Issue 10, article e46682), compared the two at the receptor level. The authors concluded that "hCG is more potent on cAMP production, while hLH is more potent on ERK and AKT activation," and that the LHCGR "is able to differentiate the activity of hLH and hCG."
For clinical purposes the more relevant difference is duration. Endogenous LH is secreted in pulses and clears within minutes. HCG persists substantially longer, which is why administration every second or third day can substitute for continuous pituitary signaling.
The Problem HCG Solves in TRT
Testosterone production is governed by the hypothalamic-pituitary-gonadal axis. The hypothalamus releases GnRH, the pituitary releases LH and FSH, and the testes respond by producing testosterone and sperm.Exogenous testosterone interrupts that loop. The hypothalamus and pituitary register adequate serum levels and reduce gonadotropin output, as documented in the Coviello data above.
Two consequences follow.
The first is testicular atrophy. Leydig cells deprived of LH stimulation reduce in volume, and most men on unsupported testosterone therapy report some reduction in testicular size within several months.
The second is suppression of spermatogenesis, and it is the more consequential of the two.
Sperm production depends on intratesticular testosterone rather than serum testosterone. The Coviello group measured baseline intratesticular testosterone at 1,174 nmol per liter against a baseline serum testosterone of 14.1 nmol per liter, meaning serum concentration represented 1.2% of the intratesticular concentration. Exogenous testosterone raises the smaller of those two numbers while collapsing the larger one.
The clinical result is well characterized. A 2013 paper in the Journal of Urology (Volume 189, Issue 4, pages 647 to 650) opens by stating that testosterone replacement therapy "results in decreased serum gonadotropins and intratesticular testosterone, and impairs spermatogenesis, leading to azoospermia in 40% of patients".
The 2010 Endocrine Society clinical practice guideline recommended against testosterone therapy outright "in those desiring fertility”.
HCG circumvents the suppression because it does not depend on pituitary output. It stimulates LHCGR directly, so Leydig cells continue producing testosterone locally irrespective of how suppressed endogenous signaling has become.
Who Benefits Most From Adding HCG?
Men who want to preserve fertility
The Coviello dose-response data quantified the effect. Post-treatment intratesticular testosterone was 25% below baseline in the 125 IU group, 7% below baseline in the 250 IU group, and 26% above baseline in the 500 IU group. The authors concluded that "relatively low dose hCG maintains ITT within the normal range in healthy men with gonadotropin suppression."Hsieh and colleagues at Baylor College of Medicine retrospectively reviewed 26 hypogonadal men, mean age 35.9 years, receiving either daily topical gel or weekly intramuscular testosterone alongside 500 IU of intramuscular HCG every other day. Pretreatment semen parameters were 2.9 mL volume, 35.2 million per mL density, and 49.0% motility. Over more than a year of follow-up, the authors reported no significant differences in semen parameters and no patient becoming azoospermic. Nine of the 26 men contributed to a pregnancy during the study period.
The sample was small, the design retrospective, and individual results vary.
Men bothered by testicular atrophy
Because HCG maintains Leydig cell activity, patients often experience preserved testicular volume, and some report partial recovery after atrophy has occurred. Men who find the change distressing should raise it with a provider rather than discontinue therapy unsupervised.Men who may discontinue TRT later
A 2015 case series in the Journal of Sexual Medicine reviewed charts from two tertiary care infertility clinics, identifying 49 men presenting with azoospermia or severe oligospermia, defined as under 1 million sperm per mL, while taking exogenous testosterone. All received 3,000 units of HCG subcutaneously every other day, supplemented with clomiphene citrate, tamoxifen, anastrozole, or recombinant FSH according to physician preference.Return of spermatogenesis or improved counts was documented in 47 of the 49 men, or 95.9%. Mean time to return was 4.6 months, with a mean first density of 22.6 million per mL. No participant discontinued because of adverse events (Wenker et al., PMID 25904023).
Those were recovery doses roughly six to twelve times typical maintenance dosing, administered under specialist supervision.
Men who report improved well-being
Some patients report better mood, libido, or general well-being on HCG combined with testosterone compared with testosterone alone. Proposed mechanisms include testicular production of pregnenolone and other steroid intermediates not restored by testosterone replacement. Controlled data supporting this are limited, and it should be treated as a possible rather than expected benefit.Why Some Clinics Skip HCG
Cost is the most common reason. HCG adds to the monthly protocol total in a market where clinics compete on advertised price. It also adds operational overhead, including a second vial, a reconstitution step, and additional patient education.There are defensible clinical reasons as well. A patient with a completed family, no concern about testicular volume, and no intention of discontinuing therapy may reasonably decline. Some providers prefer to establish a stable testosterone dose before adding adjuncts, revisiting the question at the three-month follow-up labs.
The distinction is whether the conversation occurred. A 29-year-old prescribed testosterone with no fertility discussion, no mention of enclomiphene, and no HCG offered on request represents a different situation than an informed decision to omit it.
Standard HCG Protocols in 2026
Maintenance dosing alongside testosterone therapy generally falls between 250 and 500 IU, administered subcutaneously two to three times weekly. That range derives from the Coviello dose-response findings cited above.Scheduling varies. Some protocols place HCG on non-testosterone injection days, others administer both on the same day. No strong comparative evidence favors either arrangement for maintenance purposes.
Reconstituted HCG requires refrigeration and has a limited shelf life after mixing, which affects vial sizing and reorder frequency.
None of the above constitutes a protocol to follow independently. Dosing decisions depend on baseline labs, follow-up labs, treatment goals, and provider judgment.
How to Find a Clinic That Offers HCG
Ask during intake, before payment. Three questions cover it: is HCG included in the standard protocol, is it available as an add-on, and what does it cost per month?A clinic that has considered the question typically answers directly and asks about family planning in return.
Clinics that name a medical director are more likely to publish complete protocols, since a specific licensed clinician is accountable for their content.
Some providers list adjuncts openly, presenting HCG as part of a supervised TRT protocol with dosing and pricing disclosed before signup. Whether HCG is appropriate for any individual patient still requires provider evaluation and baseline lab work. Telehealth hormone services are generally limited to patients aged 21 and older in states where the clinic's providers hold active licenses, and no clinic can promise a prescription in advance of that evaluation.
Summary
HCG is not indicated for every patient on testosterone therapy. For a man with no fertility concerns who intends to continue treatment indefinitely, omitting it is a reasonable clinical decision.For patients under 40, or any patient who may want children, the 94% reduction in intratesticular testosterone documented under unsupported testosterone therapy is a measured outcome rather than a theoretical risk. Reversal, where achieved, averaged 4.6 months in the Wenker series.
The question is worth raising at intake rather than after a semen analysis.
Educational content only, not medical advice. Individual results vary. Consult a licensed healthcare provider who has reviewed your bloodwork before starting or changing hormone therapy.
